Roche’s Neovascular AMD Drug Demonstrates Efficacy in Late-Stage Trials
Roche has announced that its investigational neovascular (wet) age-related macular degeneration (nAMD) drug, faricimab, met its primary endpoints in two global phase 3 trials.
The trials evaluated a total of 1,329 patients living with nAMD, an advanced form of AMD that can cause severe and rapid vision loss. Both studies found that patients who received injections of the antibody every 16 weeks had improved visual acuity on par with Regeneron’s rival eye drug Eylea (aflibercept).
Roche previously announced positive results in December from two phase 3 trials studying the drug as a treatment for diabetic macular edema.